Key Developments: Fuso Pharmaceutical Industries Ltd (4538.T)

4538.T on Tokyo Stock Exchange

320JPY
30 Jul 2014
Price Change (% chg)

¥-2 (-0.62%)
Prev Close
¥322
Open
¥322
Day's High
¥324
Day's Low
¥319
Volume
82,000
Avg. Vol
64,565
52-wk High
¥414
52-wk Low
¥297

Search Stocks

Latest Key Developments (Source: Significant Developments)

Fuso Pharmaceutical Industries Ltd Amends Consolidated Mid-year Outlook for FY 2014
Tuesday, 5 Nov 2013 01:00am EST 

Fuso Pharmaceutical Industries Ltd announced that it has lowered consolidated mid-year outlook for revenue from JPY 24,800 million to JPY 24,500 million, but raised the outlook for operating profit from JPY 1,400 million to JPY 1,600 million, ordinary profit from JPY 1,300 million to JPY 1,600 million, net profit from JPY 700 million to JPY 1,000 million, earnings per share from JPY 7.73 to JPY 11.05 for the fiscal year ending March 2014. The positive profit outlook is mainly due to decrease of costs.  Full Article

Gene Techno Science Co Ltd Announces Co-development Agreement with Fuso Pharmaceutical Industries Ltd
Tuesday, 14 May 2013 03:40am EDT 

Gene Techno Science Co Ltd announced that it has signed a co-development agreement with Fuso Pharmaceutical Industries Ltd, on the co-development of high-trope cell strain.  Full Article

Fuso Pharmaceutical Industries Ltd to Issue Year-end Dividend for FY 2013
Thursday, 9 May 2013 12:40am EDT 

Fuso Pharmaceutical Industries Ltd announced that it has decided to issue a year-end dividend of JPY 5 per share, above the latest dividend forecast of JPY 3 per share, disclosed on May 11, 2012, to all the shareholders of record as of March 31, 2013, effective June 28, 2013.  Full Article

Fuso Pharmaceutical Industries Ltd Announces Debt Forgiveness
Friday, 29 Mar 2013 02:00am EDT 

Fuso Pharmaceutical Industries Ltd announced a debt forgiveness of JPY 2,191 million against its wholly owned subsidiary, which is in the process of liquidation.  Full Article

Fuso Pharmaceutical Industries Ltd to Dissolve Subsidiary; Sells Asset; Expects Extraordinary Loss for FY 2013 and Profit for Q3 of FY 2013
Wednesday, 21 Nov 2012 01:00am EST 

Fuso Pharmaceutical Industries Ltd announced that it has decided to dissolve a wholly owned subsidiary, which is engaged in real estate business, based in Osaka, Japan, effective April 2013. The Company is expecting an extraordinary loss of JPY 280 million due to this development, for the fiscal year ending March 2013. The Company also announced that it has decided to sell an Osaka-based parking lot, for JPY 4,000 million in total, to a Japan-based company engaged in real estate leasing business, on December 13, 2012. The Company is expecting an extraordinary profit of JPY 2,830 million due to this development for the third quarter of fiscal year ending March 2013.  Full Article

Fuso Pharmaceutical Industries Ltd Amends Consolidated Full-year Outlook for FY 2013
Wednesday, 21 Nov 2012 01:00am EST 

Fuso Pharmaceutical Industries Ltd announced that it has reaffirmed the consolidated full-year outlook for revenue at JPY 48,000 million, operating profit at JPY 3,520 million, ordinary profit at JPY 3,120 million, but has raised the consolidated full-year outlook for net profit from JPY 1,920 million to JPY 4,290 million and earning per share from JPY 21.21 to JPY 47.38 for the fiscal year ending March 31, 2013. The positive net profit is mainly due to record of extraordinary profit.  Full Article

Fuso Pharmaceutical Industries Ltd Amends Consolidated Full-year Outlook for FY Ending March 31, 2013
Thursday, 8 Nov 2012 11:40pm EST 

Fuso Pharmaceutical Industries Ltd announced that it has reaffirmed its consolidated full-year outlook for revenue of JPY 48,000 million, and raised its consolidated full-year outlook for operating profit from JPY 2,500 million to JPY 3,520 million, ordinary profit from JPY 2,100 million to JPY 3,120 million, net profit from JPY 1,500 million to JPY 1,920 million and earning per share from JPY 16.57 to JPY 21.21 for the fiscal year ending March 31, 2013. This is due to the decreased selling and general administrative expenses.  Full Article

Fuso Pharmaceutical Industries Ltd Raises Consolidated Mid-year Outlook for FY Ending March 2013
Thursday, 1 Nov 2012 02:00am EDT 

Fuso Pharmaceutical Industries Ltd announced that it has raised its consolidated mid-year outlook for revenue from JPY 23,520 million to JPY 24,120 million, operating profit from JPY 1,220 million to JPY 2,050 million, ordinary profit from JPY 1,020 million to JPY 1,910 million, net profit from JPY 730 million to JPY 1,320 million and earning per share from JPY 8.06 to JPY 14.58 for the fiscal year ending March 2013. This is due to the influence of sales promotion, as well as the decreased selling and general administrative expenses.  Full Article

Fuso Pharmaceutical Industries Ltd Signs Semi-exclusive Distributorship Agreements with KAKEN PHARMACEUTICAL CO LTD.
Tuesday, 25 Sep 2012 02:10am EDT 

Fuso Pharmaceutical Industries Ltd announced that it has signed a semi-exclusive distributorship agreements with KAKEN PHARMACEUTICAL CO LTD., regarding joint marketing of TDM-621, which is a absorbable hemostatic material developed by 3-D Matrix Ltd.  Full Article

Search Stocks